varicella-zoster virus (live): prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
varicella-zoster virus (live): clinical details
Prescribing considerations
- Confirm susceptibility and review previous varicella infection or vaccination history.
- Assess immune disorders, immunosuppressive treatment and family history suggesting inherited immunodeficiency.
- Defer during significant febrile illness; minor illness or low-grade fever alone is not necessarily a contraindication.
- Consider rare potential vaccine-virus transmission with close contact who are susceptible pregnant people, neonates or immunocompromised people.
- For bleeding disorders, use the subcutaneous route.
- Record product name and batch number.
Contraindications and cautions
- Pregnancy
- Severe humoral or cellular immunodeficiency, symptomatic HIV infection or immune status below product-specific thresholds
- Immunosuppressive therapy, including high-dose corticosteroids
- Relevant blood dyscrasias, leukaemia, lymphoma or other malignancy affecting blood or lymphatic systems
- Active untreated tuberculosis
- Significant febrile illness
- Hypersensitivity to a varicella vaccine, an excipient or neomycin residue
- Family history of congenital or hereditary immunodeficiency unless immune competence has been demonstrated
Monitoring
- Ensure facilities and trained staff are available to manage anaphylaxis.
- Monitor higher-risk or partially immunocompromised recipients for clinical chickenpox after exposure.
- Advise prompt assessment of neurological symptoms or a significant varicella-like rash.
- Report suspected adverse reactions through the Yellow Card scheme.
Clinical pharmacology
A live attenuated Oka/Merck-strain varicella vaccine that induces humoral and cellular immune responses. Pharmacokinetic evaluation is not required for vaccines.
Formulation and product differences
- The selected VARIVAX presentation contains freeze-dried vaccine powder and supplied solvent in a pre-filled syringe.
- After reconstitution it should be a clear, colourless to pale-yellow liquid and must not be used if particles or an abnormal appearance are present.
- Use promptly after reconstitution; discard if not used within 30 minutes. Do not freeze the reconstituted vaccine.
- The formulation contains hydrolysed gelatin and may contain trace neomycin; it is essentially sodium-free and potassium-free.
varicella-zoster virus (live) interactions
Tell the vaccinator about all medicines, vaccines and blood products received recently or planned.
Immunosuppressive treatment, including high-dose corticosteroids
May cause serious infection or an inadequate response. Significant immunosuppression is a contraindication and specialist assessment may be required.
Immunoglobulins, varicella-zoster immunoglobulin, blood or plasma products
Varicella antibodies can neutralise the vaccine virus and reduce the immune response, so vaccination timing must be reviewed.
Other live viral vaccines, including MMR
They may be given at separate sites during the same visit; otherwise the vaccinator must arrange appropriate separation.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.